Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:immunologist
biologist |
| gptkbp:award |
gptkb:AACR-CRI_Lloyd_J._Old_Award_in_Cancer_Immunology
gptkb:William_B._Coley_Award |
| gptkbp:contributedTo |
development of checkpoint inhibitors
transgenic mouse technology for antibody production |
| gptkbp:degree |
gptkb:PhD
|
| gptkbp:education |
gptkb:Harvard_University
gptkb:Princeton_University |
| gptkbp:employer |
gptkb:Medarex
gptkb:Bristol-Myers_Squibb GenPharm International |
| gptkbp:field |
gptkb:biotechnology
immunology |
| https://www.w3.org/2000/01/rdf-schema#label |
Nils Lonberg
|
| gptkbp:knownFor |
contributions to cancer immunotherapy
development of fully human monoclonal antibodies work on immunotherapy |
| gptkbp:nationality |
gptkb:American
|
| gptkbp:notableWork |
Opdivo (nivolumab)
Yervoy (ipilimumab) |
| gptkbp:bfsParent |
gptkb:Medarex
|
| gptkbp:bfsLayer |
7
|